Multidisciplinary Clinic Led by world-class medical oncologist, John Deeken, MD, the

Head and Neck Cancer Clinic is held the first Tuesday and third

Thursday of each month. The Head and Neck Tumor Board

Conference meets twice monthly for case presentation and

multidisciplinary discussion.

Screening In collaboration with Inova Schar Cancer Institute, each Inova

hospital supported a Head and Neck Cancer Screening at no cost

to attendees. Volunteers included four head and neck surgeons,

one radiation oncologist and 10 support staff including nurses,

therapists, cancer registrars and Schar cancer center directors.

Physician volunteers included: Head and Neck Surgeons; Sarah Blank, MD; Alex Cheng, MD; Patty Lee, MD; Ashley O’Reilly, MD;

and Radiation Oncologist; Lonika Majithia, MD.

A total of 56 patients were provided a basic head and neck

screening where physicians looked into mouths, ears and nose,

felt for lymph nodes, and visually inspected the head and neck

region. Physicians documented normal and abnormal findings

on a screening sheet given to the patient. Further evaluation was

recommended for 28 attendees and a list of physician practices

was provided to those patients.

Head and Neck Cancer Team

Our Physicians

John Deeken, MD

Medical Oncologist

William Purkert, MD

Surgeon

Gopal Bajaj, MD

Radiation Oncologist

A six-month follow-up showed that 16 patients had seen their

physician or were scheduled to see a physician, four had not seen

a physician yet, and with further outreach, eight were unable to

be contacted.

Community Health Needs Assessment The most recent hospital Community Needs Assessment revealed

that Prince William County, located west of Inova’s primary service

area, had a cancer mortality rate higher than the state of Virginia

average for oral cavity cancers. Targeted marketing of the Head

and Neck Cancer Screening reached Prince William County and

additional communities.

*Source: Virginia Department of Health, 2012

Inova Schar Cancer Institute

With patient-centered care, Inova Schar Cancer Institute brings new hope and possibilities to those facing head

and neck cancer.

Head and Neck Cancer

2017O U T C O M E S R E P O R T

The 2017 outcomes presented are specific to Inova Schar Cancer Institute’s Head and Neck Cancer program and related support services.

Head and Neck Cancers: New Cases

100

120

140

160

80

60

40

20

0

Num

ber o

f Cas

es 2

015

and

2016

2015 2016

Female Male

Head and Neck Cancers by Gender

500

600

400

300

200

100

0

Num

ber o

f Cas

es 2

012-

201

6

Female = 211

Male = 532

2015 = 114

2016 = 148

2017 Clinical Trials

Head and Neck Cancers by Hospital and Stage

Hospital 0 I II III IV

Inova Alexandria Hospital 0 14 6 21 36

Inova Fairfax Medical Campus 9 84 61 81 230

Inova Fair Oaks Hospital 0 2 5 4 19

Inova Loudoun Hospital 1 15 8 10 22

Inova Mount Vernon Hospital 0 4 6 6 15

Inova Schar Cancer Institute (Total) 10 119 86 122 322

StageNew Cases: 2012 - 2016

The following Head and Neck Cancer trials were

available to patients at the Inova Schar Cancer Institute

in 2017. Note: Some trials as indicated are now closed

to enrollment.

Open TrialsRTOG 3504 Randomized Phase III trial of Cisplatin-based

Chemoradiotherapy (CRT) +/- Nivolumab (Anti-PD-1) in

patients with intermediate and high-risk local-regionally

advanced head and neck squamous cell carcinoma

(with lead In component). (PI: Deeken)

RTOG 1008 Randomized Phase II/III study of adjuvant

concurrent radiation and chemotherapy versus radiation

alone in resected high-risk malignant salivary gland tumors. (PI: Deeken)

A091404 Phase II Study of Enzalutamide (NSC# 766085)

for patients with androgen receptor positive salivary

cancers. (PI: Deeken)

Temporarily Closed to EnrollmentRTOG1216 Randomized Phase II/III trial of surgery and

post-operative radiation delivered with concurrent Cisplatin

versus Docetaxel versus Docetaxel and Cetuximab for

high-risk squamous cell cancer of the head and neck.

(PI: Deeken)

Closed to EnrollmentMK-3475 A Study of Pembrolizumab for first line treatment

of recurrent or metastatic squamous cell cancer of the

head and neck (MK-3475-048/KEYNOTE-048). (PI: Deeken)

BMS CA209651 An open label, randomized, two

arm Phase III study of Nivolumab in combination with

Ipilimumab versus extreme study regimen (cetuximab +

cisplatin/carboplatin + fluorouracil) as first line therapy

in recurrent or metastatic squamous cell carcinoma of

the head and neck. (PI: Deeken)

E3311 Phase II randomized trial of transoral surgical

resection followed by low-dose or standard-dose IMRT in

resectable p16+ locally advanced oropharynx cancer.

(PI: Deeken)

Head and Neck Cancer

Inova Schar Cancer Institute

G36243/1-18/PDF

2017O U T C O M E S R E P O R T